FDA's Guide to Settling Drug Debates Without Drama
Published Date: 12/23/2025
Notice
Summary
The FDA just released final guidance to help drug companies and FDA staff settle scientific disagreements through formal dispute resolution and hearings. This update affects anyone involved in drug reviews under Section 505G and aims to make the process clearer and fairer. The guidance is effective now, helping save time and avoid costly delays in drug approvals.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Final 505G Dispute-Resolution Guidance Published
On December 23, 2025 the FDA announced final guidance titled "Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act." The guidance gives recommendations for industry and review staff about formal dispute resolution (FDR) and administrative hearings for scientific or medical disputes between CDER and eligible requestors or sponsors of drugs subject to a Final Order under section 505G.
Paperwork Reduction Act Exemption for 505G Filings
Under section 505G(o) the Paperwork Reduction Act (PRA) does not apply to collections of information made under section 505G, so clearance by OMB under the PRA is not required for these collections. The guidance also references existing OMB-approved collections (for example, OMB control numbers 0910-0340 and 0910-0001).
Scope Limits and Submission Conduct Clarified
The final guidance clarifies that its recommendations are limited to FDR under section 505G(b)(2)(A)(iv)(III) and 505G(b)(4)(D)(iii) and to hearings under section 505G(b)(3). FDA removed language that could imply submitting new information outside of, or during, FDR and discouraged eligible requestors or sponsors from actively engaging other FDA entities or pursuing other regulatory or legal pathways on the same matter at the same time.
Electronic-Only Submissions Required
The guidance implements section 505G(j), which requires that all submissions related to section 505G must be in electronic format. Entities participating in FDR or hearings under section 505G must prepare and submit required materials electronically.
Consolidated Hearings Allowed for Same Order
The guidance describes procedures for consolidated proceedings and notes that under section 505G(b)(3)(C)(ii) a single hearing may be conducted if more than one request is submitted with respect to the same administrative order. The guidance also outlines best practices for consolidated appeals as required by section 505G(l)(4).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-23706, Green Mountain Power Corporation; Notice of Application Accepted for Filing, Soliciting Comments, Motions To Intervene, and Protests
Green Mountain Power wants to extend the licenses for two hydroelectric projects on Otter Creek in Vermont. This means they can keep running these power plants longer without changing how much electricity they produce. If you live nearby or care about the environment, you have until January 20, 2026, to share your thoughts or get involved before any decisions are made.
Next: 2025-23708, International Product Change-Priority Mail Express International, Priority Mail International & First-Class Package International Service Agreements
The Postal Service is updating its international shipping deals by adding new contracts for Priority Mail Express International, Priority Mail International, and First-Class Package International Service. These changes affect businesses and customers who use these services, aiming to improve options and pricing. The updates were filed on December 16, 2025, and are now under review, so expect fresh shipping choices soon!